Human clinical trials testing the efficacy of blocking the IL-4/IL-13 pathway in the three diseases have provided positive results, and anti–IL-4α, which blocks IL-4 and IL-13, is already approved for AD and AA (34–36). The gene discussed is IL4; the disease is Alzheimer disease.